2025 ANNUAL L I RESULTS N I N G C O M P A N Y L I M I T E D (INCORPORATED IN THE CAYMAN ISLANDS WITH LIMITED LIABILITY) STOCK CODES：2331 (HKD counter) and 82331 (RMB counter) DISCLAIMER 免責聲明 This presentation incorporates information contained in the annual results announcement (the "Results Announcement") for the year ended 31 December 2025 of Li Ning Company Limited (the "Company"). This presentation should be read in conjunction with the Results Announcement and is qualified in its entirety by the more d ...

2025 Annual Results 26 March 2026 R 245 G 64 B 41 R 196 G 170 B 139 R 102 G 99 B 102 R 116 G 112 B 112 R 209 G 209 B 209 R 74 G 101 B 142 R 178 G 157 B 148 R 177 G 189 B 204 R 129 G 149 B 140 Agenda Opening Remarks Vincent Lo Business Review and Outlook & Strategy Key Financial Highlights Douglas Sung Property Sales & Development Jessica Wang Commercial Asset Management Allan Zhang Chairman Stephanie Lo Vice Chairman CFO & CIO, Shui On Land CEO, Shui On Land CEO, Shui On Xintiandi R 245 G 64 B 41 R 196 G 17 ...

Opening Remarks Dr. Simon Leung NetDragon Websoft Holdings Limited Stock Code: 777 HK 2025 Annual Earnings Presentation March 27, 2026 Disclaimer This presentation is prepared by NetDragon Websoft Holdings Limited (the "Company", together with its subsidiaries referred to as the "Group" in this presentation) solely for information purposes and is not to be construed as a solicitation of an offer to buy or sell any securities of the Company in any jurisdiction. Information is given in summary form and does n ...

2025 Full Year Investor Presentation M a r 2 0 2 6 1 Legal Disclaimer 2 • This document has been prepared by YEAHKA LIMITED (the "Company" or "us") for a limited number of recipients and for information purposes only and not for public dissemination. You and your directors, officers, employees, agents and affiliates must hold this document and any oral information provided in connection with this document in strict confidence and may not communicate, reproduce, distribute or disclose it to any other person, ...

26 March 2026 2025 Annual Results 1 Disclaimer This document does not constitute an offer or invitation to purchase or subscribe for any securities or relevant derivatives of China Mobile Limited (the "Company") or the rendering of any investment advice, and no part thereof shall be relied upon or taken as the basis of any contract, commitment or investment decision relating to such securities or relevant derivatives, and this document does not constitute a recommendation in respect of the securities or rel ...

ANNUAL RESULTS PRESENTATION CONCORD NEW ENERGY GROUP LIMITED FOR THE YEAR ENDED 31 DECEMBER 2025 STOCK CODE HONG KONG : 182 | SINGAPORE : SEG incorporated in Bermuda with limited liability 2025 ANNUAL REPORT Disclaimer CONCORD NEW ENERGY GROUP LIMITED 2 • The Concord New Energy Group Limited (the "Company") hereby reminds prospective investors, financial analysts, shareholders, and other recipients of this document (the "Summary") that the contents of this Summary and any related oral discussions are for re ...

2025 Annual Results Value Growth and Service Innovation March 2026 Cautionary Statements Regarding Forward-Looking Statements To the extent any statements made in this Report contain information that is not historical, these statements are essentially forward-looking. These forward-looking statements include but are not limited to projections, targets, estimates and business plans that the Company expects or anticipates may or may not occur in the future. Words such as "potential", "estimates", "expects", " ...

Innovent Biologics 2025 Annual Results From China Leadership to Global Premier: Innovent's Definitive Path to Value and Growth March 2026 Agenda and Speakers | Business Review and Outlook | Dr. Michael Yu | Founder, Chairman of the Board, CEO | | --- | --- | --- | | R&D Highlight Updates | Dr. Hui Zhou | Chief R&D Officer, Oncology | | | Dr. Lei Qian | Chief R&D Officer, General Biomedicine | | Financials and Summary | Ms. Rachel You | Chief Financial Officer | | Q&A | Management Team | | Confidential Copyr ...

Singamas Container Holdings Limited This presentation should not, nor should anything contained in it, form the basis of or be relied upon in any connection with any contract, investment decision or commitment whatsoever; nor does it constitute a recommendation regarding the securities of Singamas. This presentation may contain forward-looking statements that involve risks and uncertainties. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking stateme ...

ile 77 ock Code : 1093) 2025 Results Presentation Mar. 2026 INNOVAT 2025 Updates Regulatory Updates New drugs approved (including new indications): Breakthrough Therapy Designations: Major Clinical Trial Progress IND approvals : North America (18) China (58) New pivotal clinical trials: From 2025 to the present, ■ BD transactions have been completed, with a billion US dollars. total amount of In 2025, the Licence fee income of billion vuan was booked in. 2 HD Envitan · Duoenvi - 1L Pancreatic cancer • Shanz ...